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Dehydrophos is a vinyl phosphonate tripeptide
produced by Streptomyces luridus with demon-
strated broad-spectrum antibiotic activity. To iden-
tify genes necessary for biosynthesis of this unusual
compound we screened a fosmid library of S. luridus
for the presence of the phosphoenolpyruvatemutase
gene, which is required for biosynthesis of most
phosphonates. Integration of one such fosmid clone
into the chromosome of S. lividans led to heterolo-
gous production of dehydrophos. Deletion analysis
of this clone allowed identification of the minimal
contiguous dehydrophos cluster, which contained
17 open reading frames (ORFs). Bioinformatic anal-
yses of these ORFs are consistent with a proposed
biosynthetic pathway that generates dehydrophos
from phosphoenolpyruvate. The early steps of this
pathway are supported by analysis of intermediates
accumulated by blocked mutants and in vitro bio-
chemical experiments.
INTRODUCTION
Dehydrophos, originally designated A53868, was first described
by Eli Lilly in 1984 as a broad-spectrum antibiotic present in
culture supernatant of Streptomyces luridus (Johnson et al.,
1984). Dehydrophos has in vitro activity against Gram-negative
and Gram-positive bacteria and demonstrated in vivo activity in
a Salmonella/chicken model system (Johnson et al., 1984). The
chemical structure of dehydrophos has been revised multiple
times, most recently in 2007 (Whitteck et al., 2007). The revised
structure of dehydrophos reveals a unique O-methylated vinyl-
phosphonate connected to a glycine-leucine dipeptide by an
amide bond. Based on similarity of the vinylphosphonate moiety
to dehydroalanine, it was proposed that the compound be
renamed dehydrophos (Whitteck et al., 2007).
Phosphonic and phosphinic acids are characterized by a C-P
bond and contain phosphorus in a reduced form (+3, +1, respec-
tively). Interest in these compounds as potential antibiotics lies
in the structural similarity shared with phosphate esters and
carboxylate-containing compounds, ubiquitous participants in402 Chemistry & Biology 17, 402–411, April 23, 2010 ª2010 Elseviercellular biology. Unlike phosphate esters, reduced phosphorus
compounds are resistant to hydrolysis and enzymatic cleavage
by phosphatases. These properties afford phosphonates the
potential to inhibit a wide variety of metabolic processes (Metcalf
and van der Donk, 2009). Indeed, known naturally occurring
phosphonates such as K-26, phosphinothricin tripeptide (PTT),
and fosfomycin (Seto and Kuzuyama, 1999) are structurally
diverse and affect diverse biological processes. Despite wide-
spread use in medicine and agriculture, understanding the bio-
synthesis of these compounds is still in a preliminary stage.
We have previously used a gene-targeted approach to identify
gene clusters required for the biosynthesis of PTT (Blodgett
et al., 2005), fosfomycin (Woodyer et al., 2006), and FR900098
(Eliot et al., 2008). This approach relies on the observation that
biosynthesis of most known phosphonates requires the enzyme
phosphoenolpyruvate (PEP) mutase (Seidel et al., 1988), with the
notable exception of the phosphonic acid K-26 (Ntai et al., 2005).
The conservation of the gene encoding PEP mutase allowed for
design of degenerate polymerase chain reaction (PCR) primers
that have proven useful in the identification of phosphonic acid
biosynthetic gene clusters from uncharacterized soil isolates
and known phosphonic acid producers. Following identification
and sequencing of the gene clusters required for the biosyn-
thesis of these reduced phosphorus compounds, bioinformatic
analysis has allowed hypothetical biosynthetic pathways to be
tested by genetic and biochemical means (Blodgett et al.,
2007; Eliot et al., 2008; Lee et al., 2009; Schwartz et al., 2004,
2005; Shao et al., 2008).
Previous studies of phosphonate biosynthesis have revealed
a wealth of unprecedented and interesting biochemistry (Blodg-
ett et al., 2007; Cicchillo et al., 2009; Liu et al., 2001). The unique
structure of dehydrophos suggested that unusual transforma-
tions would also be present in its biosynthetic pathway. Here
we report the cloning, sequencing, heterologous expression,
and mutant analysis of the dehydrophos biosynthetic gene
cluster from S. luridus and detail the early steps of the biosyn-
thetic pathway.
RESULTS
Cloning of the Dehydrophos Gene Cluster
and Heterologous Production in S. lividans
To identify genes necessary for dehydrophos biosynthesis,
a fosmid library of S. luridus NRRL 15101 was assembled inLtd All rights reserved
AB
Figure 1. Evidence of Heterologous Production of Dehydrophos in
S. lividans
(I) Bioassay demonstrating heterologous production of dehydrophos. Produc-
tion of dehydrophos was assayed against sensitive (A) and resistant (B) strains
of E. coli. Filter disks were spotted with supernatant from WM4467, synthetic
standardofdehydrophos, orsupernatant fromwild-typeS. lividans, as indicated.
(II) 31P NMR demonstrating heterologous production of dehydrophos. (A)
Supernatant collected fromWM4467. (B) As (a) but containing synthetic dehy-
drophos added as an internal standard.
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mutase gene. Of 2496 fosmid clones that were screened, 10
were PEP mutase positive. To test whether these clones con-
tained all required genes for dehydrophos production, they
were modified with helper plasmid pAE4 to allow their transfer
into the chromosome of S. lividans (Eliot et al., 2008). One
such recombinant, S. lividans WM4467, produced a compound
that inhibited the growth of E. coli DH5a, but not of an isogenic
dehydrophos resistant mutant, suggesting the strain acquired
the ability to synthesize dehydrophos. No growth inhibition
was detected using supernatant from unmodified S. lividans
(Figure 1I). Further evidence that the compound produced by
the recombinant strain was dehydrophos was provided by 31P
nuclear magnetic resonance (NMR) analysis. Supernatant from
the recombinant strain exhibits a peak in the 31P NMR spectrum
with a chemical shift of 10.2 ppm, which corresponds closely
to the chemical shift of dehydrophos from the native producer,
S. luridus. Addition of a synthetic dehydrophos standard resulted
in increased intensity of the 10.2 ppm peak and lacked the
appearance of new peaks, corroborating the identity of this
phosphonate as dehydrophos (Figure 1 II). An additional 31P
NMR peak was observed in supernatant from the heterologous
producer during longer incubations. Located at 24.5 ppm, this
peak is also present in the supernatant of the native producer
and increases in intensity over time, possibly indicating a break-
down product of the tripeptide. Control experiments revealed
that unmodified S. lividans converts dehydrophos into a com-
pound with the same 31P NMR spectrum, supporting this con-
tention (data not shown).
Sequencing, Delineation of Boundaries,
and Bioinformatic Analysis of the Gene Cluster
The fosmid clone that conferred dehydrophos production to
S. lividans was sequenced and shown to carry a 35.9 kb insert
of S. luridus genomic DNA (Figure 2). In silico sequence analyses
identified 27 potential genes within the insert. To determine
the minimal contiguous cluster required for dehydrophos pro-
duction, deletion derivatives that truncated the fosmid from
either the 50 or 30 end of the insert were constructed and trans-
ferred to the chromosome of S. lividans. The effects of these
deletions on dehydrophos production were monitored by 31P
NMR spectroscopy and bioassay. A recombinant strain lacking
ORFs 1-4 retained the ability to produce dehydrophos, whereas
a strain in which ORFs 1-5 and a portion of dhpA were removed
abolished production of dehydrophos (see Figure S1 available
online). Likewise, a strain in which ORFs 22-27 were deleted
continued to produce dehydrophos, whereas a strain in which
a portion of dhpP was deleted in addition to ORFs 22-27 was
unable to produce dehydrophos (Figure S1). These experiments
revealed that a contiguous segment of DNA, composed of
ORFs orf5 to orf21, is needed to confer dehydrophos production
on a heterologous host. Accordingly, ORFs orf6 to orf21 were
designated dhpA-dhpP.
The organization of the dhpA-dhpL genes suggests they
are cotranscribed (Figure 2). Many of these genes share overlap-
ping start/stop codons (dhpA-dhpB, dhpC-dhpD, dhpE-dhpF-
dhpG-dhpH). Three of these genes, dhpE (PEP mutase), dhpF
(phosphonopyruvate decarboxylase), and dhpG (Fe-dependent
alcohol dehydrogenase), have homologs present in multipleChemistry & Biology 17,phosphonate biosynthetic clusters (Shao et al., 2008). Bioinfor-
matic analysis, consisting of BLAST searches followed by align-
ment to representative proteins and identification of conserved
active-site residues, allowed a proposed function to be assigned
to each open reading frame (Table 1).
Mutant Analysis of dhpA-dhpP
To define the role of individual dhp genes in dehydrophos
biosynthesis, we constructed a series of plasmids with deletions
or disruptions of each gene in the biosynthetic cluster using l
red-based recombination (Datsenko and Wanner, 2000). To
prevent polar effects, these cassettes were designed to preserve
the original gene spacing in the operon, with the exception of a 6
bp AvrII scar. The resultant plasmids were then transferred into
the heterologous host S. lividans and dehydrophos production
was queried by bioassay and 31P NMR spectroscopy. Mutations
in dhpA, dhpB, dhpC, dhpD, dhpE, dhpF, dhpG, dhpH, dhpI,
dhpJ, dhpK, dhpM, and dhpP abolished antibiotic production402–411, April 23, 2010 ª2010 Elsevier Ltd All rights reserved 403
Figure 2. Gene Organization of Fosmid 17E11-4
Dark arrows indicate ORFs thought to be involved in dehydrophos biosynthesis. The solid lines indicate DNA fragments whose deletion has no effect on produc-
tion of dehydrophos, whereas the dotted lines indicate deletions that abolish production.
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Biosynthesis of the Antibiotic Dehydrophos(Figure S2) and led to the disappearance of the dehydrophos
peak from the 31P NMR spectra (Figure S3). Most of these strains
also show accumulation of new peaks in the 10-25 ppm range
(Figure S3), suggesting that intermediates are accumulating in
these blocked mutants (see below). Mutations affecting dhpL
and dhpN have no discernible effect on bioactivity (Figure S2).Table 1. Summary of 17E11 Open Reading Frames
ORF
No. of
Amino Acids Protein Homologya
orf1 509 Streptomyces lividans D-Ala-D-Ala carboxypep
orf2 469 Thermomonospora curvata FAD dependent ox
orf3 624 Salinispora arenicola polysaccharide pyruvyl tr
orf4 170 Bacillus sp. SG-1 steroid D-isomerase domain
orf5 86 Streptomyces ghanaensis putative transglycos
dhpA 299 uncultured microorganism putative g-butyrobe
dhpB 383 Vibrio splendidus glycerate kinase (YP_002394
dhpC 371 Aciduliprofundum boonei malate/L-lactate deh
dhpD 397 Candidatus Pelagibacter ubique aspartate tran
dhpE 296 Frankia alni putative PEP phosphomutase (YP_
dhpF 381 Amycolatopsis orientalis putative phosphonop
dhpG 396 Amycolatopsis orientalis putative alcohol dehy
dhpH N0 terminal domain (355 AA) Amycolatopsis ori
C0 terminal domain (343 AA)Yersinia pseudotub
protein (YP_001721344)
dhpI 218 Streptomyces clavuligerus putative S-adenosy
(YP_002193190)
dhpJ 230 Streptomyces albus peptide aspartate b-dioxy
dhpK 422 marine g proteobacterium hypothetical protein
dhpL 422 Bradyrhizobium japonicum putative integral me
dhpM 503 Frankia sp. CcI3 Na+/solute symporter (YP_481
dhpN 520 Frankia sp. CcI3 Na+/solute symporter (YP_481
dhpO 207 Frankia sp. CcI3 s-24 (YP_481568)
dhpP 339 Streptosporangium roseum lacI family transcrip
orf22 452 Actinosynnema mirum cellulase (glycosyl hydro
orf23 294 Streptomyces ambofaciens hypothetical prote
orf24 519 Streptomyces ambofaciens putative export pro
orf25 163 Streptosporangium roseum transcriptional reg
orf26 392 Streptomyces sp. Mg1 aspartate aminotransfe
orf27 350 Streptomyces sp. Mg1 hypothetical protein (YP
aResults generated by BLAST analysis of deduced open reading frames. A
404 Chemistry & Biology 17, 402–411, April 23, 2010 ª2010 ElsevierIn sum, these results indicate that all genes examined, with the
exceptions of dhpL and dhpN, are required for dehydrophos
biosynthesis.
Genetic complementation experiments were carried out on
select mutants to examine the possibility that their phenotypes
weremediated by transcriptional polarity. To do this, a functionalAmino Acid
Identity (%)
tidase (YP_002193425) 215/366 (59%)
idoreductase (ZP_04033692) 336/465 (72%)
ansferase (YP_001538394) 228/366 (62%)
protein (ZP_01861119) 51/109 (47%)
ylase associated protein (ZP_04690162) 75/81(92%)
taine hydroxylase (ABZ07908) 72/254 (28%)
749) 115/332 (35%)
ydrogenase (YP_002578914) 130/367 (35%)
saminase (ZP_01264754) 112/403 (28%)
716511) 147/275 (53%)
yruvate decarboxylase (CAB45023) 182/371(49%)
drogenase (CAB45024) 152/367(41%)
entalis putative aminotransferase (CAB45025) 169/355 (48%)
erculosis FAD linked oxidase domain-containing 101/348 (29%)
lmethionine-dependent methyltransferase 89/211 (42%)
genase (ZP_04702360) 113/230 (49%)
(YP_002651317) 72/271 (27%)
mbrane transporter (NP_774016) 160/352 (45%)
567) 274/465 (59%)
567) 307/507 (61%)
105/172 (61%)
tion regulator (ZP_04472611) 219/336 (65%)
lase family 5) ZP_03814915 193/322 (60%)
in (CAI78012) 125/228 (55%)
tein (CAJ90162) 420/527 (80%)
ulator (ZP_04478568) 112/156 (72%)
rase (YP_002180528) 305/384 (79%)
_002180529) 251/306 (82%)
ccession numbers are listed in parentheses.
Ltd All rights reserved
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Figure 3. dhpB Mutants Accumulate DHEP
31P NMR spectra of concentrated culture supernatant from a dhpBmutant (A),
and that same sample spiked with a synthetic standard of DHEP (B).
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Biosynthesis of the Antibiotic Dehydrophoscopy of the deleted gene was introduced at a distant site in the
S. lividans chromosome under the control of the constitutive
Perm* promoter. Restoration of dehydrophos biosynthesis after
complementation of the dhpB, dhpH, and dhpI mutations
demonstrates that these particular mutations were not affecting
expression of downstream genes (Figure S2). Other mutations
were not tested for polar effects due to their position in the
gene cluster (i.e., they are not upstream of any other dhp genes),
or because the mutation did not effect bioactivity. Mutant gene
clusters of dhpC and dhpJwere not tested for complementation,
and therefore the formal possibility of polar effects being respon-
sible for their observed phenotypes exists. We view this as
unlikely in the case of dhpC because the products of the down-
stream genes (dhpE, dhpF, and dhpG) are needed to produce
the intermediates observed to accumulate in the dhpC mutant
(see below).
As described above, a number of the mutants accumulated
putative phosphonate intermediates in spent media. In an
attempt to identify these compounds, authentic standards of
commercially available putative intermediates were directly
added to NMR samples containing concentrated culture super-
natant and new spectra were acquired using the same parame-
ters. In many cases, putative intermediates were unavailable
commercially, which necessitated chemical synthesis (see
Experimental Procedures). The accumulation of 2-hydroxyethyl-
phosphonate (HEP, 31P chemical shift at 19 ppm), and 1,2 dihy-
droxyethylphosphonate (DHEP, 31P chemical shift at 15.2 ppm)
in dhpA and dhpB mutants, respectively, were confirmed in
this manner (Figure 3; Figure S4). Mutations in dhpK, dhpP,
and dhpD abolished dehydrophos production based on NMR
data and bioassays (Figures S1 and S2); however, supernatants
from these strains produce a 31P NMR spectrum that contains
a phosphonate with a chemical shift of 24.5 ppm, similar to the
breakdown product witnessed in both the wild-type and heterol-
ogous producers of dehydrophos.
In Vitro Activity of DhpA
The homology of DhpA to known 2-oxoglutarate-dependent
dioxygenases, and accumulation of HEP in the supernatant of
a DdhpA mutant, led to the expectation that DhpA converted
HEP to DHEP. To test this hypothesis, the protein was overpro-
duced in E. coli as a 6X-His-tagged protein, purified, and
assayed for 2-oxoglutarate-dependent dioxygenase activity
with synthetic HEP. The reaction was monitored via 31P NMR
spectroscopy. After a 30 min incubation, the presence of
a second phosphonate peakwas observed in the 31PNMR spec-
trum (Figure 4C). Addition of authentic DHEP into the sample
confirmed that DhpA converted HEP into DHEP (Figure 4D).
This reaction occurred in a 2-oxoglutarate-dependent fashion,
but did not proceed to completion in the reaction time. Additional
experiments indicated DhpA could also convert HEP O-phos-
phomonomethylester into DHEP O-phosphomonomethylester
in a 2-oxoglutarate dependent fashion (data not shown).
Identification of a CIAP Labile Phosphonate
Intermediate
Based on 31P NMR spectroscopy, culture supernatant from
dhpC and dhpH mutants was known to contain DHEP (Figure 5
31P chemical shift at 15.2 ppm) and hypothesized to containChemistry & Biology 17,a phosphorylated form of DHEP (Figure 5, 31P chemical shift at
14.9 ppm). To test this, the supernatant was treated with calf
intestinal alkaline phosphatase (CIAP), which is expected to
hydrolyze most phosphate esters. Phosphatase treatment elim-
inated the resonance at 14.9 ppm, with a concomitant increase
in the intensity of the DHEP peak at chemical shift of 15.2 ppm
(Figure 5). The identity of DHEP was confirmed prior to and
following phosphatase treatment by addition of authentic stan-
dard. Thus the phosphonate intermediates in these mutants
contain a phosphate ester modification. This intermediate fails
to demonstrate P-P splitting in the NMR spectrum, and therefore
we feel this modification occurs at the more distally located
2-hydroxy position.
DISCUSSION
Dehydrophos is an unusual natural product with several features
that are unique among known natural products. The data pre-
sented here led to a proposed biosynthetic pathway that
accounts for the synthesis of some, but not all of these features
(Figure 6). This pathway begins with conversion of PEP to phos-
phonopyruvate (PnPy) (step I), subsequent decarboxylation
(step II) to generate phosphonoacetaldehyde (PnAA), and reduc-
tion of PnAA to yield HEP (step III). A hydroxy group is then402–411, April 23, 2010 ª2010 Elsevier Ltd All rights reserved 405
A B
C D
Figure 4. 31P NMR Spectra of DhpA Assay
HEPwas incubated with purified DhpA and a-ketoglutarate (C), incubated without enzyme (A), or incubated without a-ketoglutarate (B). The reaction shown in (C)
was then spiked with DHEP to verify the product (D).
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Biosynthesis of the Antibiotic Dehydrophosintroduced at C1 of HEP (step IV). Following this, the C2 hydroxy
group undergoes phosphorylation (step V), and the C1 hydroxy
group is oxidized (step VI), and transaminated (step VII). At this
point generation of the vinyl group is coupled to the first peptide
bond formation (step VIII). Addition of the glycine residue and
O-methylation round out completion of the dehydrophos mole-
cule (step IX).A
C
Figure 5. dhpC and dhpH Mutants Accumulate a Phosphate Ester
31PNMR spectra of concentrated culture supernatants from a dhpCmutant (A), a d
D, respectively).
406 Chemistry & Biology 17, 402–411, April 23, 2010 ª2010 ElsevierThe first two steps proposed in the pathway mirror those of
all other known phosphonate biosynthetic pathways. The PEP
mutase reaction is thermodynamically unfavorable (Bowman
et al., 1988) and often coupled to PnPy decarboxylase to yield
net synthesis of phosphonates. Based on significant amino
acid homology to biochemically characterized examples, DhpE
and DhpF catalyze the PEP mutase and PnPy decarboxylaseB
D
hpHmutant (C), and those same supernatants after treatment with CIAP (B and
Ltd All rights reserved
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Biosynthesis of the Antibiotic Dehydrophosreactions, respectively. Both of these enzymes also possess
complete conservation of residues known to be important for
catalytic activity (Jia et al., 1999; Zhang et al., 2003).
The next proposed reaction is a metal-dependent dehydroge-
nase catalyzed reduction of PnAA to HEP. This reaction is
common to several unrelated phosphonate biosynthetic path-
ways. We previously overexpressed and purified DhpG. The
enzyme was shown to be a Group III Fe-dependent PnAA dehy-
drogenase, which consumes NAD(P)H during the reduction
reaction (Shao et al., 2008).
Given the final structure of dehydrophos, biochemical logic
suggests that a free primary amine be available at C1 for peptide
bond formation. The hypothetical pathway achieves this place-
ment by hydroxylation of HEP at C1, followed by oxidation
and transamination reactions (Figure 6, steps VI and VII). The
accumulation of HEP in blocked mutants implicated DhpA
as a 2-oxoglutarate dependent dioxygenase responsible for
the hydroxylation (step IV). Subsequent in vitro experiments
confirmed this function.
DHEP is a phosphonic acid analog of glyceric acid. Thus, it
was interesting to note that DhpC has significant homology to
malate and lactate dehydrogenases, which catalyze oxidation
of similar substrates. Further, comparison of DhpC to known
malate dehydrogenases revealed conservation of all important
active site residues in DhpC (Goward and Nicholls, 1994). Based
on these observations, we expected DhpC to catalyze oxidation
of DHEP to 1-oxo, 2-hydroxyethylphosphonate (OHEP). As such,
a deletion of the dhpC gene was expected to result in the
accumulation of DHEP, which we showed has a chemical shift
of approximately 15 ppm in 31P NMR. Surprisingly, the dhpC
mutant accumulates two phosphonate intermediates with 31PChemistry & Biology 17, 402–411, April 23, 2010NMR peaks near 15 ppm, one of which
was shown to be DHEP. Treatment of
dhpC culture supernatant with alkaline
phosphatase clearly shows that the
second compound is a phosphate ester
of DHEP. Consistent with this idea, the
protein product of dhpB (located directly
upstream of dhpC) is homologous to
glycerate kinase, including conservation
of seven out of nine important active
site residues (Cheek et al., 2005). Thus,
DhpB could be responsible for phosphor-
ylation of DHEP producing 1-hydroxy-
2-phosphorylethylphosphonate (HP-EP),
the phosphonate analog of 3-phospho-
glycerate, which would represent the
second phosphonate compound seen in
culture supernatants of the dhpC mutant
(Figure 6, step V). Supernatant frommutants containing deletions of dhpB accumulate only DHEP,
suggesting that the DhpB reaction occurs before the DhpC reac-
tion. Therefore, we have assigned DhpB to step V and DhpC to
stepVI (Figure 6).
The function that phosphorylation of DHEP serves is uncertain.
During lantibiotic biosynthesis, phosphorylation precedes the
dehydration reaction involved in the formation of dehydroalanine
and dehydrobutyrine residues (Willey and van der Donk, 2007).
A similar reaction could generate the vinyl group in dehydrophos.
However, the dehydrophos gene cluster lacks ORFs with recog-
nizable homology to the enzymes that perform these dehydra-
tions in lantibiotic biosynthesis. Alternatively, phosphorylation
could provide protection from an otherwise toxic intermediate,
in a manner similar to acetylation of demethylphosphinothricin
(Blodgett et al., 2005).
Step VII is predicted to be a transamination of OHEP. DhpD
contains sequence homology to aspartate aminotransferases
and residues known to be involved in PLP binding (Inoue
et al., 1991) are conserved. Mutants lacking dhpD fail to produce
dehydrophos, as observed by 31P NMR spectroscopy and
bioassay. However, these mutants also fail to accumulate the
expected intermediates from this blockage (DHEP and HP-EP).
We suspect that endogenous aminotransferases present within
S. lividans may be able to act in a promiscuous fashion and
bypass this step in the pathway in an inefficient manner. Similar
promiscuous transaminations have been witnessed in research
on other phosphonate clusters (Blodgett et al., 2007). Pending
further investigation, we have tentatively assigned DhpD to
step VII.
The reactions putatively catalyzed by DhpB, DhpC, and DhpD
lend remarkable structural similarity between the intermediatesª2010 Elsevier Ltd All rights reserved 407
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dehydrophos pathway and those found in serine biosynthesis
(Figure 6B). Interestingly, several other phosphonate biosyn-
thetic pathways contain reactions ‘‘borrowed’’ from central
metabolic pathways (Blodgett et al., 2007; Eliot et al., 2008;
Metcalf and van der Donk, 2009). This suggests the intriguing
possibility that dehydrophos biosynthesis evolved from enzymes
of the related serine biosynthetic pathway.
The compound resulting from these reactions, 1-amino-2-
phosphorylethylphosphonate (AP-EP), is proposed to be four
steps away from dehydrophos: addition of leucine and glycine
residues, dehydration to form the vinyl group, and O-methyla-
tion. Although dehydrophos contains two peptide bonds, the
minimal cluster lacks identifiable non-ribosomal peptide synthe-
tases. It seems unlikely that dehydrophos is ribosomally synthe-
sized, because of its small size and the need for the specialized
genetic code required to identify, charge, and load a phospho-
nate precursor. The protein products of dhpH and dhpK contain
putative Acyl-CoA N-acyltransferase domains. Similar domains
are found in FemXAB family proteins responsible for peptide
bond formation during crosslinking of bacterial cell wall peptido-
glycan (Biarrotte-Sorin et al., 2004). FemXAB proteins utilize acti-
vated aminoacyl-tRNAs to generate peptide bonds. Additional
examples of aminoacyl-tRNA-based peptide bond formation in
small molecule biosynthesis (Gondry et al., 2009) make the
potential use of an analogous mechanism by DhpH and DhpK
intriguing.
The mechanism of vinyl group formation also remains uncer-
tain. It seems likely that this step occurs either simultaneously
with, or after, peptide bond formation because dehydration of
the primary amine would form an eneamine, which would
tautomerize to the imine and undergo hydrolysis. An attractive
solution to this problem is present in the ORF encoding DhpH.
The ORF encodes a large protein (698 AA) that consists of
two distinct domains. The N0-terminal domain possesses homol-
ogy to serine-glyoxylate aminotransferases and contains con-
served residues known to bind pyridoxal phosphate (PLP).
The C0-terminal domain displays homology to proteins with
oxidase activity, but further analysis by InterProScan reveals
the aforementioned N-acyl CoA acyltransferase functionality
presumably responsible for peptide bond formation. PLP-con-
taining enzymes are capable of catalyzing b-eliminations (Eliot
and Kirsch, 2004), and therefore, DhpH could eliminate the phos-
phate from intermediate VIII, generating 1-aminovinylphospho-
nate. If so, this intermediate would have to be protected from
hydrolysis to allow peptide bond formation by the second
domain. Alternatively, the vinyl group could be formed after
peptide bond formation, driven by hydrolysis of the phosphate
ester on the 1-amino-2-phosphorylethylphosphonate moiety.
Dehydrophos contains a unique O-methylation of the phos-
phonate group. A likely candidate to perform this reaction is
DhpI, which is predicted to be a SAM-dependent methyltransfer-
ase. The point at which this reaction takes place remains to be
determined, because methylated derivatives of HEP and AEP
can be seen accumulating to low amounts in dhpA and dhpJ
mutants (31P NMR peaks at approximately 25.5 ppm and 23.5
ppm, respectively). However, the concentration of methylated
early intermediates is much lower than that of the corresponding
unesterified compounds, suggesting early methylation may be408 Chemistry & Biology 17, 402–411, April 23, 2010 ª2010 Elsevieran artifact of mutations that block the pathway. Preliminary
data indicate that purified DhpA is capable of utilizing HEP
O-phosphomonomethylester as a substrate (unpublished data).
Additional enzymatic studies may clarify the preferred substrate
of DhpA.
BLAST homology analysis of the protein product of dhpL
reveals similarity to membrane transport proteins, suggesting
that DhpL is involved in self-resistance and/or export of the
finished compound. Similarly DhpM and DhpN show homology
to Na+/solute symporters and are predicted to contain the
13 transmembrane domains characteristic of these proteins.
DhpM and DhpN show remarkable homology to each other
(68% identity, 318/471 residues) suggesting they may function
as a dimer.
Finally, DhpP is homologous to s-24 transcriptional factors,
whereas DhpO is a member of the LacI repressor family of tran-
scriptional regulators. Both of these may be involved in regula-
tion of the cluster, although the specific roles they play in the
heterologous host are unknown. Orf5 falls within the segment
of DNA necessary to confer production to S. lividans. This ORF
contains a small peptide with weak homology to signal peptides
and transglycosylases. It is uncertain what role, if any, this ORF
plays in the biosynthesis of dehydrophos.
Still unaddressed are questions regarding the mode of dehy-
drophos activity. PTT and rhizocticin (an antifungal phosphonate
produced by Bacillus subtilis ATCC 6633) promote uptake by
synthesis as tripeptides that are imported by nonspecific oligo-
peptide permeases (Diddens et al., 1976; Kugler et al., 1990).
Once inside the cell, these compounds are hydrolyzed to release
biologically active phosphonate. Hydrolysis of the analogous
dehydrophos tripeptide would release 1-aminovinylphospho-
nate (a dehydroalanine analog) and result in an eneamine
expected to tautomerize to the imine and undergo hydrolysis
to produce methyl acetylphosphonate. This compound is a
potent inhibitor of pyruvate dehydrogenase, with a Ki (5 3
108 M) 125 times lower than unesterified acetylphosphonate
(O’Brien et al., 1980). This increased activity may provide a ratio-
nale for the O-methylation present on the dehydrophos phos-
phonate moiety. Methylation reduces the negative charge on
the phosphonate moiety by one, causing the charge distribution
to be more similar to a carboxylate group. This strategy of
mimicking carboxylates is similar to the C-P-C arrangement
found in PTT, but is constructed by a much simpler biosynthetic
route. Identification and manipulation of the enzyme responsible
for this reaction could lead to facile methylation of existing phos-
phonates, potentially increasing their efficacy or altering their
targets by allowing these compounds to more closely resemble
carboxylate-containing compounds.
SIGNIFICANCE
This work addresses the issue of bacterial resistance by
exploring the biosynthesis of the antibiotic dehydrophos.
Research focusing on the biosynthesis of phosphonates
as secondary metabolites is rather limited and the data pre-
sented here may be of general use in deciphering future
phosphonate gene clusters. The data raise specific ques-
tions about peptide bond formation and vinyl group forma-
tion. Although dehydrophos is a tripeptide, no identifiableLtd All rights reserved
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minimal cluster, indicating an alternate mode of peptide
bond formation. Similarly, dehydrophos contains an unusual
vinylphosphonate moiety with no obvious mechanism for
formation within the gene cluster. Understanding these
transformations could reveal unique and useful chemistry
in its own right, and aid in the combinatorial biosynthesis
of phosphonates and other small molecules. Identification
of the protein responsible for the novel methylation of the
dehydrophos molecule is particularly attractive as a means
of altering the charge distribution of the phosphonate to
resemble a carboxylate, which could prove invaluable in
downstream engineering applications. Finally this work
provides insight into the evolutionary origin of dehydrophos
biosynthesis, suggesting that portions of the pathway origi-
nated in serine biosynthesis.
EXPERIMENTAL PROCEDURES
Bacterial Strains, Plasmids, and Culture Conditions
The strains and plasmids used in this study are listed in Table S1. Strepto-
myces strains were propagated on ISP2 medium (Difco, Becton Dickinson
Microbiology Systems, Sparks, MY) at 30C. Heterologous production
cultures were inoculated with 50 ml spore stock (109 colony-forming units) of
the appropriate strain and incubated in 500 ml baffled flasks containing
100 ml nutrient broth (Difco) agitated at 250 rpm for 48 hr. E. coli was routinely
grown in Luria-Bertani broth (LB) or on 1.5% agar LB plates supplemented
appropriately. Antibiotics were used at the following concentrations to select
for plasmid propagation or integration events: ampicillin 100 mg/ml, chloram-
phenicol 10 mg/ml, apramycin 37.5 mg/ml, kanamycin 50 mg/ml. Diaminopi-
melic acid was added to media at a concentration of 1 mM for growth of
dapA strains. For dehydrophos bioassays E. coli BW13711 was grown to an
OD600 of 0.1, and then 100 ml was mixed with 2 ml molten ‘E’ media 0.5%
top agar (Vogel and Bonner, 1956) and pipetted onto ‘E’ media 1.5% agar
plates and allowed to solidify. These plates were incubated at 37C for 12 hr.
Succinate (40 mM) was provided as the carbon source during bioassays.
DNA Isolation, Manipulation, Cloning, and Sequencing
Cloning was accomplished by routine methods (Sambrook et al., 1989).
Restriction endonucleases and T4 DNA ligase were purchased from New
England Biolands (Ipswich, MA) or Invitrogen (Carlsbad, CA). KOD HotStart
polymerase (Novagen, EMD Chemicals Inc., Gibbstown, NJ) was used for
PCR amplification in combination with Failsafe PCR Premix buffers (Epicenter,
Madison, WI). Oligonucleotides were obtained from Integrated DNA Technol-
ogies (Coralville, IA). DNA fragments used in cloning experiments were isolated
by gel purification using the Promega Wizard PCR cleanup kit (Madison, WI).
Plasmid isolation was accomplished by QIAGEN Maxiprep or Miniprep kits
(Valencia, CA). Sequencing reactions were performed at theW.M. Keck Center
for Biotechnology at the University of Illinois Urbana-Champaign utilizing
primers T7-for/T7-rev or primers pBTC034-For/pBTC034-Rev. Sequence
data were compiled using Sequencer (Gene Codes Co., Ann Arbor, MI) and
deduced ORFs were subjected to BLAST (Altschul et al., 1990), InterProScan
(Zdobnov and Apweiler, 2001), and ClustalW alignments with proteins of deter-
mined function.
Generation of a S. Luridus Genomic Library, Library Screening,
and Sequencing of Fosmid 17E11-4
Construction of a S. luridus genomic library was accomplished as described
previously (Eliot et al., 2008) except WM4489 was used as the cloning host.
This library was screened by PCR for the presence of the PEP mutase gene
as previously described (Eliot et al., 2008). PCR reactions contained 1 ml culture
broth as template, 500 nM primers luridusppm-for/luridusppm-rev, and Taq
polymerase in Failsafe buffer G. To provide the functions necessary for
downstream genetic manipulation, the PEP mutase-positive fosmid clones
were recombinedwith plasmidpAE4 (Eliot et al., 2008) by in vitro recombinationChemistry & Biology 17,using BP clonase as directed by the manufacturer (Invitrogen, Carlsbad, CA).
WM4489 cells containing fosmid/pAE4 cointegrants were selected for on
LB + kanamycin following transformation. Following in vitro transposon muta-
genesis with the mini-Mu-containing BglII fragment of pAE5 (as described
by Eliot et al., 2008), sequencing of fosmid 17E11-4 was performed at the
W. M. Keck Center for Biotechnology with primers SeqAETnR/SeqAETnL.
The insert sequence has been deposited into GenBank as GU199252.
Delineation of the Minimal Contiguous Dehydrophos
Biosynthetic Cluster
Deletion constructs were generated by in vitro recombination between FRT or
loxP sites present on the fosmid backbone and corresponding sites on indi-
vidual mini-Mu transposon insertions within the cluster DNA as described
previously (Eliot et al., 2008). Following site-specific recombination catalyzed
by the appropriate recombinase (FLP or Cre), all intervening DNA between the
transposon insertion and the fosmid backbone was deleted. Conjugal transfer
of fosmids was performed as described elsewhere (Martinez et al., 2004) with
the modifications described below. The donor strain (WM6026) containing the
fosmid to be transferred was mixed with recipient S. lividans and the entire
solution was spotted onto R2 (no sucrose) plates (Kieser et al., 2000) in 10 ml
aliquots and incubated at 37C. After 12 hr, the plates were flooded with
2 ml 1 mg/ml apramycin or neomycin and returned to the incubator. After
48 hr, exconjugants were picked and restreaked twice onto selective ISP2
before PCR verification.
Generation of Additional Mutant Clusters
Three types of individual gene mutants were generated for analysis of dehy-
drophos biosynthesis; transposon inactivated mutants, gene replacements,
and gene deletions. Gene replacements and gene deletions were constructed
in WM7264 by utilizing the l Red-mediated recombination method of Dat-
senko andWanner (Datsenko andWanner, 2000). Briefly, regions of homology
upstream and downstream of the target are included on PCR primers
designed to amplify a chosen resistance cassette. Following recombination
between the PCR product and fosmid 17E11-4, the target gene is replaced
by the kanamycin resistance gene of pAE5. Gene replacements of dhpA,
dhpD, dhpM, dhpN, and dhpO were made in this fashion and retain the kana-
mycin resistance cassette. This cassette has a synthetic, outward-directed
promoter designed to express downstream genes to minimize polar effects.
The primers used in gene replacement construction also introduce an AvrII
site not present on fosmid 17E11-4, which allows for excision of the antibiotic
cassette following digestion and self-ligation of the fosmid. Digestion and self-
ligation results in deletion of the target gene and the resistance cassette,
leaving only a 6 base pair AvrII scar. Gene deletions of dhpB, dhpC, dhpE,
dhpF, dhpG, dhpH, and dhpI were constructed using the aforementioned
procedure. The remainder of the genes analyzed (dhpJ, dhpK, dhpL) are inser-
tional mutants obtained following the saturation transposon mutagenesis with
pAE5 generated for sequencing of the cluster. After PCR verification, the
mutant clusters were electroporated into WM6026 and conjugally transferred
to S. lividans as described above.
31P NMR Detection and Identification of Dehydrophos
and Phosphonate Metabolites
Culture supernatant was passed through a 0.2 micron filter, concentrated
20-fold by evaporation, and D2O was added to 25% as a lock solvent.
31P
NMR spectra were acquired on a Varian Unity Inova 600 spectrophotometer
equipped with a 5 mm AutoTuneX probe at the Varian Oxford Instrument
Center for Excellence at the University of Illinois Urbana-Champaign. An
external standard of 85% phosphoric acid was defined as 0 ppm. Supernatant
obtained following growth on liquid ISP4 (Difco) media was utilized to confirm
heterologous dehydrophos production. All other production experiments were
conducted in nutrient broth. To verify heterologous production of dehydro-
phos, an authentic standard of dehydrophos was introduced into the NMR
sample to a final concentration of 1 mM and the spectrum of the sample
was retaken using identical parameters. To demonstrate that intermediates
in the dehydrophos pathway contained a phosphate ester, 100 ml CIAP (Prom-
ega) was added directly to the NMR tube, mixed by inversion, and allowed to
incubate at 37C for one hour before reacquiring the NMR spectra under iden-
tical conditions. Experiments to confirm the identity of pathway intermediates402–411, April 23, 2010 ª2010 Elsevier Ltd All rights reserved 409
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reacquiring the spectra.
Bioassay of Dehydrophos Production
Streptomyces lividans WM4467 and the collection of isogenic dhp mutants
were grown on ISP4 plates at 30C for 48 hr. Agar cores were then taken
from these plates and placed onto bioassay medium containing either E. coli
DH5a or WM4553 (a spontaneous dehydrophos resistant mutant of DH5a).
Alternatively, filter disks spotted with 10 ml authentic standard or concentrated
culture supernatant were subjected to the same procedure as the agar cores.
These plates were incubated at 37 for 16 hr and examined for growth inhibi-
tion of the indicator strain.
Overexpression, Purification, and Activity Assay of His6-DhpA
WM7284 was grown at 37C to an OD600 of 0.6, then cooled to 22C for ten
minutes prior to the addition of 250 mM isopropyl b-D-1-thiogalactopyranoside
(IPTG) was added. The culture was incubated for an additional 18 hr at 22C
before harvesting by centrifugation at 50003 g for ten minutes. The cell pellet
was resuspended in 15 ml ice cold Buffer 1 (50 mM HEPES [pH 7.5], 250 mM
NaCl, 25 mM imidazole, and 0.5% glycerol) and cells were disrupted by a
single passage through a chilled French press cell at 20,000 psi. Solid debris
was removed by centrifugation at 13,000 3 g for 30 min at 4C. Cleared
supernatant was passed over a column containing 5 ml of Ni-NTA affinity resin
(QIAGEN, Valencia, CA) equilibrated with Buffer 1. Unbound proteins were
washed from the column with 50 ml wash Buffer 2 (Buffer 1 with 50 mM imid-
azole). His6-DhpA was eluted from the column with 5 ml Buffer 3 (Buffer 1 with
250 mM imidazole). The eluant was desalted by passage over a PD-10 column
(GE Healthcare), following the manufacturer’s instructions, and eluted with
Buffer 4 (Buffer 1 lacking imidazole). His6-DhpA purity was evaluated by visual
inspection of an SDS-PAGE gel stained with Coomassie brilliant blue (esti-
mated to be at least 95% pure). His6-DhpA activity was assayed at 30
C for
30 min in 50 mM HEPES buffer (pH 7.5), 250 mM NaCl, 0.5% glycerol. Each
1 ml reaction also included 5 mM HEP or HEP O-phosphomonomethylester,
approximately 100 mg purified protein, 5 mM 2-oxoglutarate, and 10 mM
ferrous ammonium sulfate. The reactions were stopped by incubation at
100C for 5min, and 100 ml 0.5MEDTAwas added to chelate excess Fe(II) prior
to 31P NMR analysis.
Construction of Complementation Vectors
Complementation experiments were performed using FBT1 integrating
vectors developed by Smith et al. (Gregory et al., 2003). However, these
vectors did not include a streptomycete promoter for expression purposes.
This function was included by PCR amplification and subsequent cloning of
the strong, constitutive streptomycete promoter pERM* from pANT841 into
the pRT802 vector. This resulted in the creation of pBTC034, which was
used as the vector for cloning and conjugal transfer of genes being tested
for complementation.
Chemical Syntheses of Phosphonates
All NMR spectra were recorded on Varian Unity 400 or Varian Unity 500 spec-
trometer. 1H NMR spectra are referenced to TMS at 0 ppm or H2O at 4.67 ppm,
and 13C NMR spectra are referenced to CHCl3 at 77.0 ppm. For
31P NMR
spectra, 85% phosphoric acid in D2O was used as an external reference
to 0 ppm. Fractions collected during silica gel column chromatography were
analyzed by thin-layer chromatography. Unless otherwise specified, all com-
pounds and solvents were obtained from Fisher or Aldrich. CH2Cl2 was freshly
distilled over CaH2 prior to use.
Dehydrophos (1)
Dehydrophos was synthesized and purified according to literature procedure
(Whitteck et al., 2007).
Dimethyl 1,2-Dihydroxyethylphosphonate Ester (2)
To a suspension of AD mix b (6.02 g) in 50 ml 1:1 tBuOH/H2O that had been
stirred for 15 min at room temperature (rt), dimethyl vinylphosphonate was
added dropwise (4.3 mmol, Alfa Aesar, USA) and the solution was stirred for
4 days at rt. The yellow suspension was quenched by addition of Na2SO3
(5.0 g) while on ice bath, upon which the solution turned to green. After
20 min the ice bath was removed, and the suspension was further stirred at
room temperature for another 20 min. The solution was extracted with EtOAc410 Chemistry & Biology 17, 402–411, April 23, 2010 ª2010 Elsevier(3 3 50 ml), and the combined organic layers were dried over MgSO4. After
evaporating excess solvents and reagents, the crude product was purified
by a silica gel column chromatography (EtOAc:MeOH = 4:1) to afford the
desired product in 29% yield as a colorless oil. 1H NMR (500 MHz, CDCl3)
d 4.13-4.10 (1H, m, PCH), 3.91-3.85 (2H, m, CH2), 3.83 (3H, d, J = 10.5 Hz,
OCH3), 3.82 (3H, d, J = 10.5 Hz, OCH3);
13C (125.6 MHz, CDCl3) d 68.8 (CH,
d, J = 160 Hz), 62.3, 53.3 (OCH3, d, J = 24.9 Hz);
31P (202.3 MHz, CDCl3)
d 26.9. (Stereospecific dihydroxylation by AD mix b yields enantiomerically
enriched product; however, NMR experiments described in this report do
not differentiate between enantiomers, and therefore it was not necessary
for this report to determine the enantiomeric excess of the product.)
1,2-Dihydroxyethylphosphonate Methyl Hydrogen Ester (3)
To a 10 ml round-bottomed flask charged with ester 2 (167 mg, 0.982 mmol)
was added 4.5 ml acetone and stirred at rt. To this suspension was added
p-toluene sulfonic acid (9.3 mg, 5 mol%) and further stirred overnight. The
temperature was raised on an oil bath, and the reaction mixture was refluxed
for 2 hr. After cooling, the crude product was extractedwith CH2Cl2 (33 40ml),
and the combined organic layers were dried over MgSO4. The purification was
achieved by silica gel column chromatography (EtOAc:MeOH = 10:1) to isolate
a colorless oil. To this was added 10% NaOH solution and the reaction was
heated to 100C. After refluxing for 3 hr, the reaction was acidified using 1 M
HCl, and passed through a Dowex (H+) column to yield the desired acid in
a 36.1% overall yield. 31P NMR (202.3 MHz, D2O) d 20.8.
1, 2-Dihydroxyethylphosphonic Acid (4)
To a 50 ml round-bottomed flask were added 91.8 mg (0.54 mmol) of ester 2
and 5 ml dry CH2Cl2. While stirring at rt, iodotrimethylsilane (380 mg, 3.5 Eq)
was added dropwise. After stirring at rt for 2 hr, methanolic water was added.
The excess solvents and reagents were removed under reduced pressure and
after diluting with water, the product was mixed with charcoal and filtered
through celite. 1H NMR (500 MHz, CDCl3) d 3.68 (1H, ddd, J = 10, 9, 3 Hz,
PCH), 3.60 (1H, ddd, J = 12, 7, 3 Hz, CH2), 3.43 (1H, ddd, J = 12, 9, 5.5 Hz,
CH2);
31P NMR (202.3 MHz, D2O) d 21.3.
2-Hydroxyethylphosphonate Methyl Hydrogen Ester (5)
To a solution of 10% sodium hydroxide (10 ml) was added dimethyl 2-hydrox-
yethylphosphonate ester (6.49 mmol), and refluxed for 1 hr. After the reaction
mixture was cooled to rt, it was acidified with 2 M HCl, concentrated, and
redissolved in 20 ml methanol and filtered through celite. 1H NMR (400 MHz,
CDCl3) d 3.70 (2H, dt, J = 14.4, 7.2 Hz, CH2OH), 3.35 (3H, d, J = 11.2 Hz,
OCH3), 2.01 (2H, dt, J = 18.4, 7.2 Hz, PCH2);
31P NMR (202.3 MHz) d 28.6.SUPPLEMENTAL INFORMATION
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